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A B S T R A C T
Introduction: Eosinophilia may cause organ dysfunction, but an exact relation between eosinophil blood counts
and adverse outcomes has not been described. The aim of the study is to associate in one model both normal and
increased blood eosinophil counts to the subsequent development of common conditions in internal medicine, in
which eosinophil granulocytes may play a role for the symptoms.
Methods: From the Copenhagen Primary Care Differential Count (CopDiff) Database, we identified 359,950 in-
dividuals with at least one differential cell count (DIFF) during 2000–2007. From these, one DIFF was randomly
chosen. From the Danish National Patient Register we ascertained organ damage, within four years following the
DIFF. Using multivariable logistic regression, odds ratios were calculated and adjusted for previous eosinophilia,
sex, age, year, month, CRP and comorbid conditions.
Results: Risks for skin- and respiratory disease were increased from above the median eosinophil count of
0.16×109/l and reached a plateau around 1.0×109/l. Furthermore, risks of most outcomes also increased
when the eosinophil count approached zero.
Conclusions: The observed U-shaped association with a plateau of risks around 1×109/l indicates that the risk
for symptoms due to eosinophilia do not increase proportionate at higher counts. This study demonstrates for the
first time that there is indeed an increased risk below median count of 0.16× 109/l for an increased risk for the
same manifestations. Clinically, it means that a normal or even low count of eosinophils do not rule out a risk for
organ affection by eosinophils, and may contribute to explain, why patients may have normal eosinophil counts
in e.g. asthma or allergy and still have symptoms from the lungs and skin, most likely explained by the extra-
vasation of eosinophils.
1. Introduction
In healthy individuals, eosinophilic granulocytes (eosinophils)
constitute less than five percent of all white blood cells [1]. Blood eo-
sinophilia, traditionally defined for use in clinical practice as an eosi-
nophil count of ≥0.5×109/l, is encountered in all areas of medicine
and in both primary and secondary care. It may arise from either clonal
intrinsic disorders or from reactive extrinsic conditions [2–4]. Reactive
causes account for the vast majority of cases. A plethora of distinct
disease entities with concomitant eosinophilia has been known for
many years, while the primary eosinophilic conditions were not in-
troduced until 1968 [1,5–7].
For the prognostic evaluation and management of patients
presenting with eosinophilia it is important to identify both the many
patients with reactive eosinophilia and those patients with the rarer
specific clonal diseases. This leaves a very small subgroup of patients
with idiopathic hypereosinophilia [3,4,7,8], where neither clonality nor
other primary stimuli can be demonstrated. Several useful algorithms
for such workup have been presented.
The eosinophilic granulocyte may have diverse physiological func-
tions, which in principle are beneficial in the immune reaction against
exogenous (infections) and endogenous (inflammation and cancer) in-
truders [9,10]. However, irrespective of the cause of eosinophilia, the
activation of eosinophils may also result in inappropriate organ in-
volvement due to tissue invasion and release of cytokines, peptides,
metabolites and proteinases from the granule matrix or cell surface
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[1,2]. Accordingly, organ involvement from both clonal and reactive
causes has been reported and such deleterious effects may be one of the
initial manifestations of eosinophil-related disease [3,7,9,10].
So far, no association between levels of blood eosinophils and organ
manifestations has been demonstrated. However, it seems as if eosi-
nophils show a predilection for certain organ systems such as heart
[11–17], lungs [18–23], gastrointestinal system [24–27], nervous
system [28–35] and skin [36–40]. A scoring system guiding therapy
based on certain paraclinical determinations was introduced some
thirty years ago for patients with idiopathic hypereosinophilic syndrome
[41,42], but this has not been implemented in clinical work, and today
the degree of blood eosinophilia as mild (≥0.5×109/l-1.5× 109/l),
moderate (≥1.5×109/l-5.0× 109/l) and severe (≥5.0× 109/l) is
arbitrary and not based on risk stratification for organ manifestations
[1,3].
This is the first study to examine both normal and increased number
of blood eosinophils and the development of various common medical
conditions. The rationale for this study was to investigate the number of
eosinophil granulocytes in blood samples and the subsequent risk in the
same individual subjects in a large population-based cohort to develop
disorders with organ involvement, where eosinophils may play a pa-
thophysiological role, in order to reflect a functional context, which has
not been established previously.
2. Methods
The Copenhagen General Practitioners’ Laboratory (CGPL) served
the general practitioners (GPs) in the Copenhagen area up until 2016
and covered approximately 1.3 million inhabitants. CGPL had
International Organization for Standardization (ISO) accreditation and
has registered all analytical results since May 1, 2000. The Copenhagen
Primary Care Differential Count (CopDiff) database contains results
from all differential cell counts (DIFFs) requested by GPs in
Copenhagen from July 1, 2000 to January 25, 2010. From each of the
359,950 unique individuals (aged 18–80 years) with at least one DIFF
in the period January 1, 2001 to December 31, 2007, a single DIFF
encompassing the eosinophil count was randomly chosen by computer-
generated random numbers (n= 356,196; Fig. 1). Eosinophil test re-
sults reported as “<0.02×109/l” were set to “0.0×109/l” in order to
maintain only numeric values in the database (n=1889). Where
available, the level of C-reactive-protein (CRP), categorized as “in-
creased” (≥10mg/l) vs. “normal” (< 10mg/l) was also obtained from
the database (n=229,511). Furthermore, we recorded whether an-
other DIFF was made during the 6 months before our request
(n= 32,475) and whether eosinophilia was present in this DIFF. In
November 2013, the CopDiff database was linked to The Danish Na-
tional Patient Register (NPR) which has recorded information on all
contacts since 1977 with hospitals in Denmark, including discharge
diagnoses, outpatient clinic contacts and surgical procedures per-
formed; and to which reporting is mandatory by law in Demark [43].
Outcomes was potentially eosinophil-related organ damage (taken
from the NPR) over the 4-year period following the DIFF defined ac-
cording to the ICD nomenclature and grouped as: “Cardiac disease”,
“Skin disease”, “Neurological disease”, “Gastrointestinal disease” and
“Respiratory disease”. Please refer to the Supplementary Table 1 for
details on these entities and references. To adjust for possible con-
founding by comorbid conditions, we also computed Charlson's Co-
morbidity Index (CCI) [44] from the hospital contacts recorded in the
NPR for three years before the DIFF. The study was approved by the
Danish Data Protection Agency. According to Danish legislation no
ethical approval or patient consent was required since the patients were
not approached at any time during the conduct of the study However, it
is not possible without access to each individual patient file to de-
termine the time elapsed from symptoms to blood sampling to diag-
nosis.
3. Statistical analysis
We used multivariable logistic regression to calculate the odds ratio
(OR) for the 4 -year incidences of the outcomes between the eosinophil
count and a baseline count of 0.16× 109/l which was the median eo-
sinophil count in our data. This OR was adjusted for previous eosino-
philia, sex, age, year, month, CRP and competing comorbid conditions
(CCI), and modelled as a restricted cubic spline [45]. In order to assess
only de novo cases of potential eosinophil-related end-organ damage,
individuals who had already experienced organ damage (since three
years prior to index DIFF blood sampling) were excluded from risk
analyses. A Chi-squared test was used for comparison of the observed
distributions of incident disease within the five organ damage groups
between the eosinophil groups of “ < 0.16x109/l” and “≥0.16x109/l”.
All analyses and calculations were performed with SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA). This study was registered by The Danish
Data Protection Agency J.nr. 2013-231-0053 and by www.
researchregistry.com UIN 4955.
4. Results
In the full cohort of 359,950 individuals there was a female/male
sex ratio of 1.38 (208,691/151,259) and a mean age (SD) of 48.3 (16.7)
years. Of these, 14,406 individuals (4%) had eosinophilia
(≥0.5×109/l). Compared with the baseline count of 0.16×109/l
which was the median eosinophil count in our data, risks for skin- and
respiratory disease were increased both above and below the definition
of eosinophilia (Table 1). At the 99th percentile, corresponding to an
eosinophil count of 0.75×109/l, risks of respiratory end-organ damage
were increased more than two-fold with OR (95% C.I.) of 2.11
(1.96–2.27, P < 0.001). The corresponding risk increase estimate for
skin disease was 1.88 (1.64–2.15, P < 0.001).
Odds ratios of 2 may be interpreted given the number of specific
patients in Table 2. Notwithstanding this, the model to obtain results
included logistic regression and adjustments as described to capture
only de novo cases.
Furthermore, risks of cardiac, neurological and gastrointestinal
disease also increased below the median eosinophil count. To illustrate
this non-linear relationship, we used restricted cubic splines of the ORs
for the outcomes according to the eosinophil count (Fig. 2). These risk
curves were U-shaped for all outcomes and the median eosinophil count
of 0.16× 109/l represented the lowest risk for most outcomes. In ad-
dition, all risks reached a plateau at an eosinophil count around
1.0×109/l, above which the risks did not increase noticeably.
We then compared incident diagnoses below and above the median
eosinophil count of 0.16×109/l in an attempt to unmask the me-
chanisms behind the observed increases in risk for low eosinophil
counts. Although overall differences were statistically significant for all
groups besides “Skin disease”, and this was most likely due to large
numbers, no marked differences in frequency distributions were ob-
served (Table 2).
5. Discussion
In this study on almost 360,000 individuals, we demonstrate that
irrespective of the definition of eosinophilia, eosinophil numbers as-
sociate with the subsequent diagnosis of a potential eosinophil-related
skin- or respiratory condition even below such a threshold, and that
these risks reach a plateau around approximately 1.0× 109/l. It is
possible that these observations explain why a clear relationship be-
tween eosinophilia and eosinophil related end-organ damage and
prognosis has previously been difficult to demonstrate [41,42]. It is
important to bear in mind that a eosinophil blood measurement re-
presents a balance between production and cell turnover, but does not
take into account the extravasation of eosinophils from blood to tissues,
where the cell perform its functions without returning to the
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circulation. Hence, the upper normal range of 0.5 eosinophils x 109/l is
arbitrary in the context of organ involvement. Therefore, the associa-
tion of eosinophil counts in individual patients to pathophysiologic
relations has to be based on the observed median value, not the normal
distribution. In this large population, the median eosinophil count of
0.16×109/l was applied as reference to assess cases of potential eo-
sinophil-related end-organ manifestations. Interestingly, the exact same
median value was observed in a Dutch population of 13,301 subjects
studied for complex metabolic and pulmonary traits and diseases [46].
The plateau of risks of potential eosinophil-related end-organ
symptoms around 1.0× 109/l is important for the management of pa-
tients with both reactive and clonal eosinophilia since mild-to-moderate
eosinophilia, according to traditional definitions, associates with si-
milar risks of subsequent adverse events as severe eosinophilia. It is
important to note that this study is not able to determine the impact of
medical intervention on the observed risks. Akin to these observations,
a non-linear platelet binding to von-Willebrand factor is observed in
thrombocytosis [47], and it is also known that patients with essential
thrombocythaemia do not necessarily exhibit higher risks of thrombosis
with increasing platelet counts per se [48,49].
Fig. 1. Flowchart. CGPL, Copenhagen General Practitioners' Laboratory; CopDiff, Copenhagen Primary Care Differential Count; CRS, The Danish Civil Registration
System; DIFF, differential cell count; GP, general practitioner.
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Increases in risks of skin and respiratory disease were much greater
than for the remaining outcomes which were negligible. Such variation
could be an expression of the many different risk factors involved in the
development of the different outcomes in this study where, as an ex-
ample, eosinophil-associated cardiac disease constitutes an insignificant
proportion of all cardiac outcomes. The implementation of the
Charlson's Comorbidity Index to adjust for competing comorbid con-
ditions only allows for rudimentary adjustment for non-eosinophil-re-
lated disease. Decreased risks of respiratory disease with low eosinophil
counts are observed in our results, however, this finding is a con-
sequence of the chosen baseline eosinophil count of 0.16×109/l and
does not reflect a protective effect.
All analyses share the U-shaped dose-response relationship (Fig. 2),
also termed hormesis [50]. These U-shaped curves have been reported
for various endpoints of considerable significance to public health, such
as longevity and cancer incidence. In all cases it seems as if either too
much or too little of a certain stimulus is associated with sub-optimal
biological performance [51,52]. In the present setting, the detrimental
effect of low eosinophil levels on risks of eosinophil-related end-organ
symptoms may reflect the biological process where eosinophils leave
the peripheral blood to enter the tissues in order to perform their
physiological tasks. This would mimic the extravasation of neutrophils
in infection [53,54]. This would also be in accordance with the de-
monstration of eosinophils in tissue specimens as part of the diagnostic
criteria in vasculitis [55] and the inflammatory process of atopic der-
matitis [40] and asthma [23]. Hence, a suspected phenomenon of ex-
travasation is important, because it converts the eosinophil count into a
prognostic factor for potential end-organ involvement.
We did not observe outspoken differences in diagnoses when com-
paring the distributions below and above the median eosinophil count
(Table 2), but odds ratio for the four-year incidence of potential eosi-
nophil-related end-organ-damage for the indicated eosinophil count
compared to the median eosinophil count showed very different rela-
tions (Fig. 2).
This study was designed to isolate the possible association, and thus
an impact on the predilection for certain organs, of the number of eo-
sinophil granulocytes measured in a blood sample, in a statistical model
in a very large well-defined cohort. Other blood cells than eosinophils
may also leave the circulation by diapedesis, like neutrophil granulo-
cytes, whereas thrombocytes remain in the circulation. However, these
blood cells have different turnover and cellular dynamic and make it
difficult to interpret the functional interplay of eosinophils and other
cells in the individual subject, analysed in one blood sample at a given
time point.
The CopDiff database has some important strengths. Firstly, access
to all DIFFs from all GPs on some 360,000 individuals from the
Copenhagen area over a 10-year period offers a unique insight from a
population sample that covers approximately 20% of the entire popu-
lation of Denmark. Furthermore, the CopDiff population was sampled
continuously without any restrictions as to why the DIFF was requested
by the GP. This, together with the use of a computer-generated random
selection among these DIFFs, diminishes selection bias which would
have been more likely if opting for, for instance, “the first DIFF” or “the
DIFF closest to an outcome of interest”. Secondly, all diagnoses in this
study were derived from the NPR, which was established in 1977, and
to which reporting is mandatory. Validity of the register is secured
through quality control routines applied in the daily production and
completion of annual reports [43,56]. Thirdly, The CopDiff database
comes from a population which can be assumed to exhibit disease to a
greater extent than the general population. The use of logistic regres-
sion analysis on the four-year incidence ensures that measures of excess
risk (OR) can be interpreted independently of the frequency of the
outcomes in the study. The OR is therefore a valid estimate for excess
risk in the general population as well [57].
This study also has several limitations. Firstly, we were not able to
identify the different causes of eosinophilia in the DIFFs. However,Ta
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eosinophil-related organ damage may occur irrespective of the cause of
eosinophilia which renders this information less important in the pre-
sent study. Certainly, most patients in this study registered with eosi-
nophilia have a reactive condition, because primary causes are so rare.
Secondly, we performed risk analysis on de novo cases of potential end-
organ disease as reported in the NPR. We cannot rule out, however, that
some conditions have evolved since prior to blood sampling due to
developmental latency of some disease entities. Likewise, we did not
have information about drug treatment. Some types of drugs are known
to cause eosinophilia [2] whereas others, especially glucocorticoids, are
known to induce eosinophilic apoptosis [58]. Systemic glucocorticoids
may be a relevant treatment in asthma, but not in heart conditions. And
still the hormesis phenomenon is observed. A potential confounding
effect of steroids should be a matter of interest in future studies.
Thirdly, the NPR only holds information on individuals who have been
in contact with secondary care and therefore patients exclusively
managed in primary care are not included in present analyses. Lastly,
we did not have access to clinical information about the patients, such
as weight, smoking, alcohol consumption, exercise patterns, and family
history of disease. These are associated with several types of cancer and
certain benign conditions. The relation of these clinical variables to the
eosinophil count is less clear and not examined in detail [59,60], or do
not show any major direct association [61].
Eosinophils may cause organ dysfunction either by secretion from
circulating cells of eosinophil constituents or by tissue invasion of the
activated granulocyte [1,2,9,10]. The observed plateau of risks around
1×109/l may indicate to the physician managing eosinophilia that the
risk do not increase proportionate at higher counts (Fig. 2), which has
been a dilemma previously. In addition, this study demonstrates that
there is indeed an increased risk below median count of 0.16×109/l
for an increase in odds-ratio for the same medical diagnoses. Clinically,
it means that a normal or even low count of eosinophils do not justify to
rule out a risk for organ affection by eosinophils, but on the contrary
may contribute to explain, why patients may have normal eosinophil
counts in e.g. asthma or allergy and still have symptoms from lungs and
skin. Most likely, the interpretation which may combine these results is
a relation to eosinophil trafficking and dynamics. An alternative in-
terpretation than extravasation of the low numbers of eosinophils in
blood could be an inhibition of production, or destruction of eosino-
phils. However, there is no consequence of not having eosinophils in
this context [62], why this interpretation cannot explain the observed
association with end-organ symptoms (Tables 1 and 2 and Fig. 2).
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Table 2
The distribution of incident cases of disease (within 4 years from DIFF) in eosinophil groups.
Type Eosinophils < 0.16×109/l, n Percent within group Eosinophils ≥0.16× 109/l, n Percent within group
Cardiac disease, individuals at risk= 346,211a
Pericardium 124 1.7% 172 1.8%
Endocardium 61 0.9% 43 0.5%
Valve 510 7.2% 713 7.6%
Myocardium 146 2.1% 175 1.9%
Conduction 3916 55.2% 4997 53.0%
Heart failure 1812 25.6% 2653 28.2%
Other heart disease 521 7.3% 671 7.1%
Total, P=0.0002† 7090 100.0% 9424 100.0%
Skin disease, individuals at risk=353,249a
Dermatitis and eczema 1.427 76.3% 1933 77.6%
Urticaria and erythema 444 23.7% 557 22.4%
Total, P=0.29† 1871 100.0% 2490 100.0%
Neurological disease, individuals at risk= 350,308a
Degenerative diseases of the nervous system 545 13.6% 587 10.8%
Mononeuritis multiplex 6 0.1% 17 0.3%
Polyneuropathies 812 20.3% 1065 19.6%
Paralytic syndromes 175 4.4% 247 4.5%
Encephalopathy, unspecified 16 0.4% 27 0.5%
Cerebrovascular disease 2447 61.2% 3501 64.3%
Total, P=0.0004† 4001 100.0% 5444 100.0%
Gastrointestinal disease, individuals at risk= 345,370a
Diseases of esophagus, stomach and duodenum 4100 53.9% 5239 55.5%
Non-infective enteritis and colitis 1668 21.9% 2170 23.0%
Diseases of liver 1235 16.3% 1298 13.7%
Disorders of gallbladder, biliary tract and pancreas 597 7.9% 738 7.8%
Total, P < 0.0001† 7600 100.0% 9445 100.0%
Respiratory disease, individuals at risk= 345,524a
Chronic lower respiratory disease 4811 83.2% 8045 85.5%
Respiratory disease principally affecting the interstitium 429 7.4% 619 6.6%
Pleural disease 540 9.3% 743 7.9%
Total, P=0.0006† 5780 100.0% 9407 100.0%
a In order to assess only de novo cases of potential eosinophil-related end-organ damage, individuals who had already experienced organ damage (since three years
prior to index DIFF blood sampling) were excluded from analyses, please refer to Fig. 1 for details.† Chi-squared test for the overall comparison of distributions
between the groups.
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Fig. 2. Odds ratio (OR) for the four-year incidence of potential eosinophil-related end-organ-damage for the indicated eosinophil count compared to a baseline count
of 0.16×109/l (the median eosinophil count in our data). The shaded area around the line denotes the 95% confidence interval.
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